COMMUNIQUÉS West-GlobeNewswire

aTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results and Provides Corporate Update
19/03/2018
SAN DIEGO, March 19, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today [...]
Delcath to Present at Oppenheimer 28th Annual Healthcare Conference
19/03/2018
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, [...]
Opiant Pharmaceuticals, Inc. to Present a Corporate Overview at the Oppenheimer 28th Annual Healthcare Conference
19/03/2018
SANTA MONICA, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT ), a specialty pharmaceutical company developing pharmacological treatments for addictions, announced today [...]
HealthEquity Reports Fourth Quarter and Fiscal Year Ended January 31, 2018 Financial Results
19/03/2018
Highlights of the fiscal year include: Revenue of $229.5 million, an increase of 29% compared to FY17. Net income of $47.4 million, an increase of 80% compared to FY17. Net income per diluted share of $0.77, compared to [...]
AIT Therapeutics Reports Year End 2017 Financial Results
19/03/2018
Expects first regulatory filing for the NO Generator and Delivery System in persistent pulmonary hypertension of the newborn (PPHN) by end of 2018 Closed global, exclusive license for revolutionary NO Generator and [...]
Rhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR, POMC, And PCSK1 Variants at ENDO 2018
19/03/2018
BOSTON, March 19, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM ), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of [...]
Molecular Templates to Present at the Oppenheimer 28th Annual Healthcare Conference
19/03/2018
AUSTIN, Texas, March 19, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM ) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new [...]
Avinger Announces Fourth Quarter and Full Year 2017 Results
19/03/2018
REDWOOD CITY, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR ) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported [...]
Emblem Selects No Fixed Address as its Agency of Record
19/03/2018
TORONTO, March 19, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV:EMC) (TSXV:EMC.WT) (" Emblem " or the " Corporation ") is pleased to announce that it has selected No Fixed Address ( “NFA” ) as its agency of record, [...]
Soricimed annonce la nomination du Dr Marc Rubin et de M. Vaughn Embro-Pantalony à son conseil d’administration
19/03/2018
MONCTON, Nouveau-Brunswick, 19 mars 2018 (GLOBE NEWSWIRE) -- Soricimed Biopharma Inc. (« Soricimed »), compagnie pharmaceutique au stade clinique spécialisée dans la recherche et la mise au point de thérapies contre le [...]
Soricimed Announces the Appointment of Dr. Marc Rubin and Mr. Vaughn Embro-Pantalony to Board of Directors
19/03/2018
MONCTON, New Brunswick, March 19, 2018 (GLOBE NEWSWIRE) -- Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage pharmaceutical company discovering and developing targeted cancer therapeutics, is pleased to announce [...]
Extraordinary General Meeting of Active Biotech AB
19/03/2018
PRESS RELEASE NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR [...]
OSE Immunotherapeutics to Present New Data on OSE-172 at American Association for Cancer Research Annual Meeting 2018, in Chicago, April 14-18
19/03/2018
OSE-172, SIRPa Antagonist: Prevents Metastasis Spread in Aggressive Cancer Models; Decreases Tumor Growth and Suppressive Function of Tumor Myeloid Cells, MDSC and M2 Macrophages, in Various Cancers Models; Potentiates [...]
Transactions under Novozymes’ stock buyback program
19/03/2018
Please read the full announcement in the attached PDF 2018_09_Stock_Buybackprogram_EN
pSivida Announces FDA Acceptance For Filing of New Drug Application (NDA) for Durasert™ Three-Year Treatment for Posterior Segment Uveitis
19/03/2018
WATERTOWN, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ: PSDV ) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today announced that its New Drug [...]
Ossur Hf : Transactions in relation to share buyback program
19/03/2018
Announcement no. 22/2018 Reykjavik, 19 March 2018 Transactions in relation to share buyback program On 5 March 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 16/2018. The purpose of the [...]
NICOX :Document de reference 2017
19/03/2018
Nicox : Document de reference 2017 ................................................ 19 mars 2018 Sophia Antipolis, France Le Document de référence 2017 de la société Nicox SA, incluant le rapport financier annuel visé à [...]
Study Shows Positive Results with Medtronic Cryoballoon for Patients with Persistent Atrial Fibrillation
19/03/2018
DUBLIN and BARCELONA, Spain - MARCH 19, 2018 - Medtronic plc (NYSE: MDT) today announced one-year results from the CRYO4PERSISTENT AF study of ablation with the Arctic Front Advance(TM) Cryoballoon to isolate the [...]
Tivity Health to Issue First Quarter 2018 Financial Results After Market Close on April 23
19/03/2018
Nashville, Tenn., March 19, 2018 (GLOBE NEWSWIRE) -- Tivity Health, Inc. (NASDAQ: TVTY) today announced that its financial results for the first quarter ending March 31, 2018, will be released after market close on [...]

Pages